deferiprone has been researched along with losartan potassium in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beuzard, Y; Dalle, B; Payen, E | 1 |
| Atisuk, K; Chantraluksri, U; Fucharoen, S; Hoffbrand, AV; Kachintorn, U; Maungsub, W; Pootrakul, P; Sankote, J; Shalev, O; Sirankapracha, P; Sriphen, K; Thakernpol, K | 1 |
| Cermák, J | 1 |
| Friedman, LS; Lynch, DR; Tsou, AY; Wilson, RB | 1 |
| Cermak, J; Hochova, I; Jonasova, A; Neuwirtova, R; Siskova, M; Vondrakova, J; Walterova, L | 1 |
1 review(s) available for deferiprone and losartan potassium
| Article | Year |
|---|---|
Pharmacotherapy for Friedreich ataxia.
Topics: Animals; Antioxidants; Deferiprone; Enzyme Inhibitors; Erythropoietin; Friedreich Ataxia; Histone Deacetylase Inhibitors; Humans; Iron Chelating Agents; Organophosphorus Compounds; Pyridones; Recombinant Proteins; Ubiquinone | 2009 |
3 trial(s) available for deferiprone and losartan potassium
| Article | Year |
|---|---|
Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand.
Topics: Administration, Oral; Adult; beta-Thalassemia; Deferiprone; Erythrocyte Membrane; Erythropoietin; Female; Ferritins; Hemoglobin E; Humans; Iron; Iron Chelating Agents; Liver; Male; Middle Aged; Pyridones; Receptors, Transferrin; Thailand; Thiobarbituric Acid Reactive Substances | 2003 |
Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy.
Topics: Administration, Oral; Anemia, Refractory; Deferiprone; Drug Administration Schedule; Drug Therapy, Combination; Erythropoietin; Female; Ferritins; Humans; Injections, Subcutaneous; Iron; Iron Chelating Agents; Myelodysplastic Syndromes; Pyridones; Recombinant Proteins | 2006 |
Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Deferiprone; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Erythropoietin; Female; Ferritins; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Pyridones; Recombinant Proteins; Treatment Outcome | 2011 |
1 other study(ies) available for deferiprone and losartan potassium
| Article | Year |
|---|---|
Modulation of transduced erythropoietin expression by iron.
Topics: Animals; Cell Line; Deferiprone; Erythropoietin; Gene Expression Regulation; Gene Transfer Techniques; Genetic Therapy; Hemin; Humans; Iron; Iron Chelating Agents; Mice; Mice, Inbred C3H; Oxygen Consumption; Pyridones; Transgenes | 2000 |